Effects of sevoflurane on leucine-rich repeat kinase 2-associated Drosophila model of Parkinson's disease

被引:8
|
作者
Shan, Zhiming [1 ]
Cai, Song [2 ]
Zhang, Tao [1 ]
Kuang, Liting [1 ]
Wang, Qi [2 ]
Xiu, Huanhuan [1 ]
Wen, Jing [1 ]
Gu, Huaiyu [2 ]
Xu, Kangqing [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Anesthesiol, Guangzhou 510080, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Anat & Neurobiol, Guangzhou 510080, Guangdong, Peoples R China
关键词
sevoflurane; Drosophila; LRRK2; Parkinson's disease; patch clamp; TARGETED GENE-EXPRESSION; SYNAPTIC-TRANSMISSION; RECEPTOR ACTIVATION; NEONATAL EXPOSURE; MUSHROOM BODY; ANTENNAL LOBE; KENYON CELLS; NEURONS; PATHOGENESIS; ISOFLURANE;
D O I
10.3892/mmr.2014.2966
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with Parkinson's disease (PD) often require surgery, and therefore may receive inhalation anesthesia. However, it is currently unknown whether inhalation anesthetics affect the prognosis of the disease. Leucine-rich repeat kinase 2 (LRRK2) genetic mutations are the most common cause of familial PD, contributing to similar to 39% of all cases in certain populations. The aim of the present study was to determine the effects of inhaled anesthetics on PD, by observing the influence of sevoflurane on a LRRK2-associated Drosophila model of PD. PD transgenic Drosophila overexpressing LRRK2 were generated by crossing flies expressing an LRRK2 upstream activation sequence, with tyrosine hydroxylase (TH)-Gal4 flies. Western blot analysis successfully verified that the transgenic Drosophila overexpressed LRRK2. Three days prior to eclosion, three genotypes of Drosophila were divided into four groups, and were exposed to air, 1, 2, or 3% sevoflurane, for 5 hours. Twenty-four hours after the exposure, the electrophysiological activities of the projection neurons (PN) in the brains of the Drosophila were recorded using a patch clamp. The locomotor activities were tested on days 5, 10, 15, 20, 25, 30, 35 and 40 following eclosion. The frequency of miniature excitatory synaptic currents (mEPSCs) obtained from the PNs of the TH-wild type LRRK2 (TH-WT) Drosophila brain, following exposure to air (1.60+/-0.05 Hz), was lower as compared with the wild type LRRK2 (WT) (2.51+/-0.07 Hz) and W1118 (2.41+/-0.10 Hz) Drosophila. After exposure to 1, 2 and 3% sevoflurane, the frequency of mEPSCs in the brains of the TH-WT group decreased to 0.82+/-0.04 Hz, 0.63+/-0.16 Hz and 0.55+/-0.04 Hz, respectively. The percentage decrease of the frequency of mEPSCs, from exposure to air to 1% sevoflurane, of the TH-WT group (48.32%+/-3.08%) was significantly higher, as compared with the WT (39.17%+/-1.42%) and W1118 (35.10%+/-2.66%) groups, and there was no statistical difference between the WT and W1118 groups. The transgenic TH-WT Drosophila presented an early decrease in locomotor ability, as compared with the WT and W1118 groups. Following a 5 hour exposure to sevoflurane, the percentage decrease of the climbing abilities of the TH-WT group, from exposure to air to 1% sevoflurane, were significantly lower, as compared with the WT and W1118 groups. In conclusion, sevoflurane had negative effects on the control W1118 flies, and also severely aggravated the prognosis of PD in the LRRK2-associated Drosophila model, through synaptic cholinergic deficits and impairment on locomotor abilities.
引用
收藏
页码:2062 / 2070
页数:9
相关论文
共 50 条
  • [21] Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain
    Higashi, Shinji
    Moore, Darren J.
    Colebrooke, Rebecca E.
    Biskup, Saskia
    Dawson, Valina L.
    Arai, Heii
    Dawson, Ted M.
    Emson, Piers C.
    JOURNAL OF NEUROCHEMISTRY, 2007, 100 (02) : 368 - 381
  • [22] Colonic Leucine-Rich Repeat Kinase 2 Expression Is Increased and Associated With Disease Severity in Patients With Parkinson's Disease
    Liao, Peng-Hsiang
    Chiang, Han-Lin
    Shun, Chia-Tung
    Hang, Jen-Fan
    Chiu, Han-Mo
    Wu, Ming-Shiang
    Lin, Chin-Hsien
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 13
  • [23] A new approach to Parkinson's disease: inhibition of leucine-rich repeat kinase-2
    Doggrell, Sheila A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (04) : 587 - 590
  • [24] Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2
    Tong, Youren
    Shen, Jie
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 1042 - 1046
  • [25] Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease
    Domingos, Sofia
    Duarte, Teresa
    Saraiva, Lucilia
    Guedes, Rita C.
    Moreira, Rui
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (15) : 1953 - 1977
  • [26] A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation
    Ahamadi, Malidi
    Mehrotra, Nitin
    Hanan, Nathan
    Lai Yee, Ka
    Gheyas, Ferdous
    Anton, Judith
    Bani, Massimo
    Boroojerdi, Babak
    Smit, Hans
    Weidemann, Jonas
    Macha, Sreeraj
    Thuillier, Vincent
    Chen, Chao
    Yang, Minhua
    Williams-Gray, Caroline H.
    Stebbins, Glenn T.
    Pagano, Gennaro
    Hang, Yaming
    Marek, Kenneth
    Venuto, Charles S.
    Javidnia, Monica
    Dexter, David
    Pedata, Anne
    Stafford, Bob
    Akalu, Mussie
    Stephenson, Diane
    Romero, Klaus
    Sinha, Vikram
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (02) : 508 - 518
  • [27] Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs
    Ahamadi, Malidi
    Conrado, Daniela J.
    Macha, Sreeraj
    Sinha, Vikram
    Stone, Julie
    Burton, Jackson
    Nicholas, Timothy
    Gallagher, Jill
    Dexter, David
    Bani, Massimo
    Boroojerdi, Babak
    Smit, Hans
    Weidemann, Jonas
    Chen, Chao
    Yang, Minhua
    Maciuca, Romeo
    Lawson, Rachael
    Burn, David
    Marek, Kenneth
    Venuto, Charles
    Stafford, Bob
    Akalu, Mussie
    Stephenson, Diane
    Romero, Klaus
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (03) : 553 - 562
  • [28] Structure, function, and leucine-rich repeat kinase 2: On the importance of reproducibility in understanding Parkinson's disease
    Cookson, Mark R.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (30) : 8346 - 8348
  • [29] Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients
    Tan, Yu-yan
    Wu, Li
    Zhao, Zong-bo
    Wang, Ying
    Xiao, Qin
    Liu, Jun
    Wang, Gang
    Ma, Jian-fang
    Chen, Sheng-di
    PARKINSONISM & RELATED DISORDERS, 2014, 20 (03) : 308 - 313
  • [30] The Incidence of Mutation on the Leucine-rich Repeat Kinase 2 Gene in Patients with Parkinson's Disease in Slovakia
    Kracunova, K.
    Kovacovicova, M.
    Baldovic, M.
    Valkovic, P.
    Kadasi, L'
    Benetin, J.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2011, 74 (04) : 443 - 445